Photothermal therapies to improve immune checkpoint blockade for cancer

References

• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Martins GA, Tadokoro CE, Silva RB, et al. CTLA-4 blockage increases resistance to infection with the intracellular protozoan Trypanosoma cruzi. J Immunol. 2004;172(8):4893–4901.
   PubMed Web of Science ®Google Scholar
• Walker L. CTLA-4 and autoimmunity: new twists in the tale. Trends Immunol. 2015;36(12):760–762.
   PubMed Web of Science ®Google Scholar
• Paterson AM, Lovitch SB, Sage PT, et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med. 2015;212(10):1603–1621.
   PubMed Web of Science ®Google Scholar
• Ariyan C, Salvalaggio P, Fecteau S, et al. Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J Immunol. 2003;171(11):5673–5677.
   PubMed Web of Science ®Google Scholar
• Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19(1):225–252.
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer immunology. N Engl J Med. 2008;358(25):2704–2715.
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7–19.
   PubMed Web of Science ®Google Scholar
• Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015;15(3):149–159.
   PubMed Web of Science ®Google Scholar
• Borst J, Ahrends T, Bąbała N, et al. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18(10):635–647.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211(1):214–224.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192(2):303–310.
   PubMed Web of Science ®Google Scholar
• Scheipers P, Reiser H. Role of the CTLA-4 receptor in t cell activation and immunity. Physiologic function of the CTLA-4 receptor. Immunol Res. 1998;18(2):103–115.
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459–465.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1(9):793–801.
   PubMed Web of Science ®Google Scholar
• Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600–603.
   PubMed Web of Science ®Google Scholar
• Walker LSK, Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol. 2015;36(2):63–70.
   PubMed Web of Science ®Google Scholar
• Salmaninejad A, Valilou SF, Shabgah AG, et al. PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol. 2019;234(10):16824–16837.
   PubMed Web of Science ®Google Scholar
• Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535.
   PubMed Web of Science ®Google Scholar
• Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–11.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010;37(5):473–484.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588.
   PubMed Web of Science ®Google Scholar
• Kaehler KC, Piel S, Livingstone E, et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol. 2010;37(5):485–498.
   PubMed Web of Science ®Google Scholar
• Bajwa R, Cheema A, Khan T, et al. Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res. 2019;11(4):225–236.
   PubMedGoogle Scholar
• Bakos O, Lawson C, Rouleau S, et al. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6(1):86.
   PubMed Web of Science ®Google Scholar
• Wang C, Sun W, Ye Y, et al. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nat Biomed Eng. 2017;1(2):0011.
   Web of Science ®Google Scholar
• Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44(2):343–354.
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–443.
   PubMed Web of Science ®Google Scholar
• Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3(4):345–355.
   PubMed Web of Science ®Google Scholar
• Derer A, Frey B, Fietkau R, et al. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother. 2016;65(7):779–786.
   PubMed Web of Science ®Google Scholar
• Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci. 2003;100(23):13549–13554.
   PubMed Web of Science ®Google Scholar
• O’Neal DP, Hirsch LR, Halas NJ, et al. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 2004;209(2):171–176.
   PubMed Web of Science ®Google Scholar
• Huang X, Jain PK, El-Sayed IH, et al. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci. 2008;23(3):217–228.
   PubMed Web of Science ®Google Scholar
• Dickerson EB, Dreaden EC, Huang X, et al. Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Lett. 2008;269(1):57–66.
   PubMed Web of Science ®Google Scholar
• de Bruijne M, Holt B, van Rhoon GC, et al. Evaluation of CEM43°CT90 thermal dose in superficial hyperthermia. Strahlenther Onkol. 2010;186(8):436–443.
   PubMed Web of Science ®Google Scholar
• P. D. Maguire TVSLRPELJGLRBPLWLDMBS. A phase II trial testing the thermal dose parameter CEM43° T90 as a predictor of response in soft tissue sarcomas treated with pre-operative thermoradiotherapy. Int J Hyperthermia. 2001;17(4):283–290.
   PubMed Web of Science ®Google Scholar
• Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10(6):787–800.
   PubMed Web of Science ®Google Scholar
• van Rhoon GC, Aleman A, Kelfkens G, et al. Health council of the Netherlands: no need to change from SAR to time-temperature relation in electromagnetic fields exposure limits. Int J Hyperthermia. 2011;27(4):399–404.
   PubMed Web of Science ®Google Scholar
• Yarmolenko PS, Moon EJ, Landon C, et al. Thresholds for thermal damage to normal tissues: an update. Int J Hyperthermia. 2011;27(4):320–343.
   PubMed Web of Science ®Google Scholar
• Sordillo LA, Pu Y, Pratavieira S, et al. Deep optical imaging of tissue using the second and third near-infrared spectral windows. J Biomed Opt. 2014;19(5):056004.
   PubMed Web of Science ®Google Scholar
• Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol. 2001;19(4):316–317.
   PubMed Web of Science ®Google Scholar
• Burke A, Ding X, Singh R, et al. Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci USA. 2009;106(31):12897–12902.
   PubMed Web of Science ®Google Scholar
• Sweeney EE, Cano-Mejia J, Fernandes R. Photothermal therapy generates a thermal window of immunogenic cell death in neuroblastoma. Small. 2018;14(20):1800678.
   PubMed Web of Science ®Google Scholar
• Nam J, Son S, Ochyl LJ, et al. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun. 2018;9(1):1074.
   PubMed Web of Science ®Google Scholar
• Sweeney EE, Burga RA, Li C, et al. Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Sci Rep. 2016;6(1):37035.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhan X, Xiong J, et al. Temperature-dependent cell death patterns induced by functionalized gold nanoparticle photothermal therapy in melanoma cells. Sci Rep. 2018;8(1):8720.
   PubMed Web of Science ®Google Scholar
• Perez-Hernandez M, Del Pino P, Mitchell SG, et al. Dissecting the molecular mechanism of apoptosis during photothermal therapy using gold nanoprisms. ACS Nano. 2015;9(1):52–61.
   PubMed Web of Science ®Google Scholar
• Ren Y, Qi H, Chen Q, et al. Thermal dosage investigation for optimal temperature distribution in gold nanoparticle enhanced photothermal therapy. Int J Heat Mass Transf. 2017;106:212–221.
   Web of Science ®Google Scholar
• van Rhoon GC, Samaras T, Yarmolenko PS, et al. CEM43 °C thermal dose thresholds: a potential guide for magnetic resonance radiofrequency exposure levels? Eur Radiol. 2013;23(8):2215–2227.
   PubMed Web of Science ®Google Scholar
• Ledezma DK, Balakrishnan PB, Cano-Mejia J, et al. Indocyanine green-nexturastat A-PLGA nanoparticles combine photothermal and epigenetic therapy for melanoma. Nanomaterials. 2020;10(1):161.
   Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3(9):e955691.
   PubMed Web of Science ®Google Scholar
• Cano-Mejia J, Bookstaver ML, Sweeney EE, et al. Prussian blue nanoparticle-based antigenicity and adjuvanticity trigger robust antitumor immune responses against neuroblastoma. Biomater Sci. 2019;7(5):1875–1887.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yang J, Zhang Y, et al. Local phototherapy synergizes with immunoadjuvant for treatment of pancreatic cancer through induced immunogenic tumor vaccine. Clin Cancer Res. 2018;24(21):5335–5346.
   PubMed Web of Science ®Google Scholar
• Bear AS, Kennedy LC, Young JK, et al. Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer. PLoS One. 2013;8(7):e69073.
   PubMed Web of Science ®Google Scholar
• Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234–241.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–931.
   PubMed Web of Science ®Google Scholar
• Abdo J, Cornell DL, Mittal SK, et al. Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers. Front Oncol. 2018;8:85.
   PubMed Web of Science ®Google Scholar
• Cano-Mejia J, Shukla A, Ledezma DK, et al. CpG-coated Prussian blue nanoparticles-based photothermal therapy combined with anti-CTLA-4 immune checkpoint blockade triggers a robust abscopal effect against neuroblastoma. Transl Oncol. 2020;13(10):100823.
   PubMed Web of Science ®Google Scholar
• Chen Q, Hu Q, Dukhovlinova E, et al. Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells. Adv Mater. 2019;31(23):1900192.
   PubMed Web of Science ®Google Scholar
• Min Y, Roche KC, Tian S, et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol. 2017;12(9):877–882.
   PubMed Web of Science ®Google Scholar
• Wang M, Song J, Zhou F, et al. NIR-triggered phototherapy and immunotherapy via an antigen-capturing nanoplatform for metastatic cancer treatment. Adv Sci. 2019;6(10):1802157.
   Web of Science ®Google Scholar
• Zhou F, Nordquist RE, Chen WR. Photonics immunotherapy — A novel strategy for cancer treatment. J Innov Opt Health Sci. 2016;09(01):1630001.
   Web of Science ®Google Scholar
• Hou X, Tao Y, Pang Y, et al. Nanoparticle-based photothermal and photodynamic immunotherapy for tumor treatment. Int J Cancer. 2018;143(12):3050–3060.
   PubMed Web of Science ®Google Scholar
• Liu Y, Crawford BM, Vo-Dinh T. Gold nanoparticles-mediated photothermal therapy and immunotherapy. Immunotherapy. 2018;10(13):1175–1188.
   PubMed Web of Science ®Google Scholar
• Liu Y, Maccarini P, Palmer GM, et al. Synergistic immuno photothermal nanotherapy (SYMPHONY) for the treatment of unresectable and metastatic cancers. Sci Rep. 2017;7(1):8606.
   PubMed Web of Science ®Google Scholar
• Zhou B, Song J, Wang M, et al. BSA-bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by combined photothermal therapy and immunotherapy. Nanoscale. 2018;10(46):21640–21647.
   PubMed Web of Science ®Google Scholar
• Luo L, Yang J, Zhu C, et al. Sustained release of anti-PD-1 peptide for perdurable immunotherapy together with photothermal ablation against primary and distant tumors. J Control Release. 2018;278:87–99.
   PubMed Web of Science ®Google Scholar
• Luo L, Zhu C, Yin H, et al. Laser immunotherapy in combination with perdurable PD-1 blocking for the treatment of metastatic tumors. ACS Nano. 2018;12(8):7647–7662.
   PubMed Web of Science ®Google Scholar
• Ge R, Liu C, Zhang X, et al. Photothermal-activatable Fe3O4 superparticle nanodrug carriers with PD-L1 immune checkpoint blockade for anti-metastatic cancer immunotherapy. ACS Appl Mater Interfaces. 2018;10(24):20342–20355.
   PubMed Web of Science ®Google Scholar
• Chen H, Luan X, Paholak HJ, et al. Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy. Nanomedicine. 2020;15(1):77–92.
   PubMed Web of Science ®Google Scholar
• Zhang N, Song J, Liu Y, et al. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma. J Control Release. 2019;306:15–28.
   PubMed Web of Science ®Google Scholar
• Cano-Mejia J, Burga RA, Sweeney EE, et al. Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. Nanomedicine. 2017;13(2):771–781.
   PubMed Web of Science ®Google Scholar
• Olson TY, Schwartzberg AM, Orme CA, et al. Hollow gold − silver double-shell nanospheres: structure, optical absorption, and surface-enhanced Raman scattering. J Phys Chem C. 2008;112(16):6319–6329.
   Web of Science ®Google Scholar
• Liang X, Ye X, Wang C, et al. Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation. J Control Release. 2019;296:150–161.
   PubMed Web of Science ®Google Scholar
• Wang R, He Z, Cai P, et al. Surface-functionalized modified copper sulfide nanoparticles enhance checkpoint blockade tumor immunotherapy by photothermal therapy and antigen capturing. ACS Appl Mater Interfaces. 2019;11(15):13964–13972.
   PubMed Web of Science ®Google Scholar
• Yan M, Liu Y, Zhu X, et al. Nanoscale reduced graphene oxide-mediated photothermal therapy together with IDO inhibition and PD-L1 blockade synergistically promote antitumor immunity. ACS Appl Mater Interfaces. 2019;11(2):1876–1885.
   PubMed Web of Science ®Google Scholar
• Wang C, Xu L, Liang C, et al. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv Mater Weinheim. 2014;26(48):8154–8162.
   PubMed Web of Science ®Google Scholar
• Chen Q, Xu L, Liang C, et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun. 2016;7(1):13193.
   PubMed Web of Science ®Google Scholar
• Tian Y, Wang X, Zhao S, et al. JQ1-loaded polydopamine nanoplatform inhibits c-MYC/programmed cell death ligand 1 to enhance photothermal therapy for triple-negative breast cancer. ACS Appl Mater Interfaces. 2019;11(50):46626–46636.
   PubMed Web of Science ®Google Scholar
• Chen W, Guo Z, Zhu Y, et al. Combination of bacterial-photothermal therapy with an anti-PD-1 peptide depot for enhanced immunity against advanced cancer. Adv Funct Mater. 2020;30(1):1906623.
   Web of Science ®Google Scholar
• Lu Q, Qi S, Li P, et al. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy. J Mater Chem B. 2019;7(15):2499–2511.
   PubMed Web of Science ®Google Scholar
• Huang L, Li Y, Du Y, et al. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Nat Commun. 2019;10(1):4871.
   PubMed Web of Science ®Google Scholar
• Bardhan R, Lal S, Joshi A, et al. Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc Chem Res. 2011;44(10):936–946.
   PubMed Web of Science ®Google Scholar
• Lal S, Clare SE, Halas NJ. Nanoshell-enabled photothermal cancer therapy: impending clinical impact. Acc Chem Res. 2008;41(12):1842–1851.
   PubMed Web of Science ®Google Scholar
• Loo C, Lin A, Hirsch L, et al. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat. 2004;3(1):33–40.
   PubMed Web of Science ®Google Scholar
• Cheng X, Sun R, Yin L, et al. Light-triggered assembly of gold nanoparticles for photothermal therapy and photoacoustic imaging of tumors in vivo. Adv Mater. 2017;29(6):1604894.
   Web of Science ®Google Scholar
• Vines JB, Yoon JH, Ryu NE, et al. Gold nanoparticles for photothermal cancer therapy. Front Chem. 2019;7:167.
   PubMed Web of Science ®Google Scholar
• Riley RS, Day ES. Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(4):.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee D. Near-infrared-responsive cancer photothermal and photodynamic therapy using gold nanoparticles. Polymers-Basel. 2018;10(9):961.
   PubMed Web of Science ®Google Scholar
• van Landeghem FKH, Maier-Hauff K, Jordan A, et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials. 2009;30(1):52–57.
   PubMed Web of Science ®Google Scholar
• Shen S, Wang S, Zheng R, et al. Magnetic nanoparticle clusters for photothermal therapy with near-infrared irradiation. Biomaterials. 2015;39:67–74.
   PubMed Web of Science ®Google Scholar
• Estelrich J, Busquets M. Iron oxide nanoparticles in photothermal therapy. Molecules. 2018;23(7):1567.
   PubMed Web of Science ®Google Scholar
• Ge R, Li X, Lin M, et al. Fe3O4@polydopamine composite theranostic superparticles employing preassembled Fe3O4 nanoparticles as the core. ACS Appl Mater Interfaces. 2016;8(35):22942–22952.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109–118.
   PubMed Web of Science ®Google Scholar
• Chao JL, Savage PA. Unlocking the complexities of tumor-associated regulatory T cells. J Immunol. 2018;200(2):415–421.
   PubMed Web of Science ®Google Scholar
• Thompson DF, Church CO. Prussian blue for treatment of radiocesium poisoning. Pharmacotherapy. 2001;21(11):1364–1367.
   PubMed Web of Science ®Google Scholar
• Delchet C, Tokarev A, Dumail X, et al. Extraction of radioactive cesium using innovative functionalized porous materials. RSC Adv. 2012;2(13):5707–5716.
   Web of Science ®Google Scholar
• Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):157.
   PubMed Web of Science ®Google Scholar
• Bonaventura P, Shekarian T, Alcazer V, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168.
   PubMed Web of Science ®Google Scholar
• Li M, Wang Y, Lin H, et al. Hollow CuS nanocube as nanocarrier for synergetic chemo/photothermal/photodynamic therapy. Mater Sci Eng C Mater Biol Appl. 2019;96:591–598.
   PubMed Web of Science ®Google Scholar
• Jiang L, Han J, Li J, et al. Photothermal therapy of cancer cells using novel hollow gold nanoflowers. Int J Nanomedicine. 2014;9:517.
   PubMed Web of Science ®Google Scholar
• Song Y, Wang Y, Wang S, et al. Immune-adjuvant loaded Bi2Se3 nanocage for photothermal-improved PD-L1 checkpoint blockade immune-tumor metastasis therapy. Nano Res. 2019;12(8):1770–1780.
   Web of Science ®Google Scholar
• Shao J, Xie H, Huang H, et al. Biodegradable black phosphorus-based nanospheres for in vivo photothermal cancer therapy. Nat Commun. 2016;7(1):12967.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu Z, Hou Y, et al. Multifunctional nanoplatform based on black phosphorus quantum dots for bioimaging and photodynamic/photothermal synergistic cancer therapy. ACS Appl Mater Interfaces. 2017;9(30):25098–25106.
   PubMed Web of Science ®Google Scholar
• Chen W, Ouyang J, Liu H, et al. Black phosphorus nanosheet-based drug delivery system for synergistic photodynamic/photothermal/chemotherapy of cancer. Adv Mater. 2017;29(5):1603864.
   Web of Science ®Google Scholar
• Lee HU, Park SY, Lee SC, et al. Black phosphorus (BP) nanodots for potential biomedical applications. Small. 2016;12(2):214–219.
   PubMed Web of Science ®Google Scholar
• Guo T, Wu Y, Lin Y, et al. Black phosphorus quantum dots with renal clearance property for efficient photodynamic therapy. Small. 2018;14(4):1702815.
   Web of Science ®Google Scholar
• Qi H, Liu C, Long L, et al. Blood exosomes endowed with magnetic and targeting properties for cancer therapy. ACS Nano. 2016;10(3):3323–3333.
   PubMed Web of Science ®Google Scholar
• Li SY, Qiu WX, Cheng H, et al. A versatile plasma membrane engineered cell vehicle for contact-cell-enhanced photodynamic therapy. Adv Funct Mater. 2017;27(12):1604916.
   Web of Science ®Google Scholar
• Gao W, Hu CM, Fang RH, et al. Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater Weinheim. 2013;25(26):3549–3553.
   PubMed Web of Science ®Google Scholar
• Tian Q, Jiang F, Zou R, et al. Hydrophilic Cu9S5 nanocrystals: a photothermal agent with a 25.7% heat conversion efficiency for photothermal ablation of cancer cells in vivo. ACS Nano. 2011;5(12):9761–9771.
   PubMed Web of Science ®Google Scholar
• Tian Q, Tang M, Sun Y, et al. Hydrophilic flower-like CuS superstructures as an efficient 980 nm laser-driven photothermal agent for ablation of cancer cells. Adv Mater Weinheim. 2011;23(31):3542–3547.
   PubMed Web of Science ®Google Scholar
• Patel KD, Singh RK, Kim HW. Carbon-based nanomaterials as an emerging platform for theranostics. Mater Horiz. 2019;6(3):434–469.
   Web of Science ®Google Scholar
• Zeng Y, Yang Z, Li H, et al. Multifunctional nanographene oxide for targeted gene-mediated thermochemotherapy of drug-resistant tumour. Sci Rep. 2017;7(1):43506.
   PubMed Web of Science ®Google Scholar
• Chen YW, Chen PJ, Hu SH, et al. NIR-triggered synergic photo-chemothermal therapy delivered by reduced graphene oxide/carbon/mesoporous silica nanocookies. Adv Funct Mater. 2014;24(4):451–459.
   Web of Science ®Google Scholar
• Prendergast GC, Malachowski WP, Duhadaway JB, et al. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 2017;77(24):6795–6811.
   PubMed Web of Science ®Google Scholar
• Labadie BW, Bao R, Luke JJ. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis. Clin Cancer Res. 2019;25(5):1462–1471.
   PubMed Web of Science ®Google Scholar
• Peng J, Xiao Y, Li W, et al. Combined photothermal therapy and immunotherapy: photosensitizer micelles together with IDO inhibitor enhance cancer photothermal therapy and immunotherapy (Adv. Sci. 5/2018). Adv Sci. 2018;5(5):1870031.
   Web of Science ®Google Scholar
• Xing L, Gong JH, Wang Y, et al. Hypoxia alleviation-triggered enhanced photodynamic therapy in combination with IDO inhibitor for preferable cancer therapy. Biomaterials. 2019;206:170–182.
   PubMed Web of Science ®Google Scholar
• Li X, Fan Y, Watari F. Current investigations into carbon nanotubes for biomedical application. Biomed Mater. 2010;5(2):22001.
   PubMed Web of Science ®Google Scholar
• Kostarelos K, Bianco A, Prato M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat Nanotechnol. 2009;4(10):627–633.
   PubMed Web of Science ®Google Scholar
• Firme CP, Bandaru PR. Toxicity issues in the application of carbon nanotubes to biological systems. Nanomedicine. 2010;6(2):245–256.
   PubMed Web of Science ®Google Scholar
• De La Zerda A, Zavaleta C, Keren S, et al. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol. 2008;3(9):557–562.
   PubMed Web of Science ®Google Scholar
• Vardharajula S, Ali SZ, Tiwari PM, et al. Functionalized carbon nanotubes: biomedical applications. Int J Nanomedicine. 2012;7:5361–5374.
   PubMed Web of Science ®Google Scholar
• Zhou B, Li Y, Niu G, et al. Near-infrared organic dye-based nanoagent for the photothermal therapy of cancer. ACS Appl Mater Interfaces. 2016;8(44):29899–29905.
   PubMed Web of Science ®Google Scholar
• Zheng M, Yue C, Ma Y, et al. Single-step assembly of DOX/ICG loaded lipid-polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS Nano. 2013;7(3):2056–2067.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ai K, Lu L. Polydopamine and its derivative materials: synthesis and promising applications in energy, environmental, and biomedical fields. Chem Rev. 2014;114(9):5057–5115.
   PubMed Web of Science ®Google Scholar
• Casey SC, Tong L, Li Y, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352(6282):227–231.
   PubMed Web of Science ®Google Scholar
• Bagley AF, Hill S, Rogers GS, et al. Plasmonic photothermal heating of intraperitoneal tumors through the use of an implanted near-infrared source. ACS Nano. 2013;7(9):8089–8097.
   PubMed Web of Science ®Google Scholar
• He J, Wilson BC, Piao D, et al. Diffuse optical tomography to monitor the photocoagulation front during interstitial photothermal therapy: numerical simulations and measurements in tissue-simulating phantoms. Photon Laser Med. 2014;3(3):241–254.
   Google Scholar
• Kannadorai RK, Liu Q. Optimization in interstitial plasmonic photothermal therapy for treatment planning. Med Phys. 2013;40(10):103301.
   PubMed Web of Science ®Google Scholar
• Liu S, Doughty A, West C, et al. Determination of temperature distribution in tissue for interstitial cancer photothermal therapy. Int J Hyperthermia. 2018;34(6):756–763.
   PubMed Web of Science ®Google Scholar